Nymox Pharmaceutical Corporation (NYMXF)
USD 0.14
(-8.36%)
USD 0.14
(-8.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.84 Million USD | -34.49% |
| 2022 | -6.57 Million USD | 47.55% |
| 2021 | -12.53 Million USD | -6.81% |
| 2020 | -11.73 Million USD | 10.82% |
| 2019 | -13.16 Million USD | -24.24% |
| 2018 | -10.59 Million USD | 21.11% |
| 2017 | -13.42 Million USD | -2.43% |
| 2016 | -13.11 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -1.03 Million USD | 6.67% |
| 2023 Q4 | -5.31 Million USD | -412.64% |
| 2023 Q2 | -1.11 Million USD | 19.97% |
| 2023 Q1 | -1.38 Million USD | -3.58% |
| 2022 Q1 | -5.08 Million USD | -81.0% |
| 2022 Q2 | 1.34 Million USD | 126.35% |
| 2022 Q4 | -1.33 Million USD | 10.19% |
| 2022 FY | -6.57 Million USD | 47.55% |
| 2022 Q3 | -1.49 Million USD | -211.27% |
| 2021 Q4 | -2.81 Million USD | 14.8% |
| 2021 FY | -12.53 Million USD | -6.81% |
| 2021 Q3 | -3.29 Million USD | 0.0% |
| 2020 FY | -11.73 Million USD | 10.82% |
| 2019 FY | -13.16 Million USD | -24.24% |
| 2018 FY | -10.59 Million USD | 21.11% |
| 2017 FY | -13.42 Million USD | -2.43% |
| 2016 FY | -13.11 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -562.258% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -26.653% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 116.693% |
| Nascent Biotech, Inc. | -2.08 Million USD | -323.628% |
| Rebus Holdings, Inc. | -1.02 Million USD | -767.059% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 113.578% |
| Qrons Inc. | -789.34 Thousand USD | -1020.42% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1298.466% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 85.872% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2028.627% |
| Skye Bioscience, Inc. | -37.64 Million USD | 76.507% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 88.202% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -34.487% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -3134.797% |
| SQZ Biotechnologies Company | -79.46 Million USD | 88.87% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -205.767% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -385.793% |
| Mesoblast Limited | -87.95 Million USD | 89.945% |
| Marizyme, Inc. | -65.34 Million USD | 86.466% |
| Genus plc | 7.9 Million USD | 211.949% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 18.801% |
| Pharming Group N.V. | -10.54 Million USD | 16.155% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -307.593% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -138.368% |
| ContraFect Corporation | -65.15 Million USD | 86.426% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -81.005% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -411.967% |
| IMV Inc. | -36.48 Million USD | 75.76% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -9.731% |
| MultiCell Technologies, Inc. | -380.07 USD | -2326839.774% |
| ONE Bio Corp. | 8.67 Million USD | 201.929% |
| Accustem Sciences Inc. | -3.74 Million USD | -136.065% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 82.891% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -597.953% |
| Q BioMed Inc. | -2.05 Million USD | -330.975% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -136.914% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -271.461% |
| Biomind Labs Inc. | -1.21 Million USD | -628.309% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 85.192% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -185.128% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -11.906% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -353.713% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -58954.487% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 44.277% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -52.031% |
| GB Sciences, Inc. | -1.36 Million USD | -549.493% |
| Alpha Cognition Inc. | -13.77 Million USD | 35.785% |
| HST Global, Inc. | -146.21 Thousand USD | -5948.834% |
| CSL Limited | 2.64 Billion USD | 100.335% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -403.997% |
| Halberd Corporation | -79.67 Thousand USD | -10999.955% |
| Enzolytics Inc. | -2.17 Million USD | -306.278% |
| Agentix Corp. | -1.37 Million USD | -543.569% |
| Resverlogix Corp. | -3.61 Million USD | -144.986% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -178.864% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 97.003% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 9124.49% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 227.719% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -122.603% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -192.254% |
| AVAX Technologies, Inc. | -6.41 Million USD | -37.893% |
| Zenith Capital Corp. | -10.59 Million USD | 16.535% |
| Genscript Biotech Corporation | -95.47 Million USD | 90.737% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -37951.803% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -113.317% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -14532.546% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -341.072% |
| Kadimastem Ltd | -3.3 Million USD | -167.401% |
| Helix BioMedix, Inc. | -1.05 Million USD | -737.455% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -131.579% |
| BioStem Technologies, Inc. | -8.48 Million USD | -4.256% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1903.766% |
| LadRx Corporation | 400.44 Thousand USD | 2308.554% |
| Cell Source, Inc. | -5.32 Million USD | -66.203% |
| Regen BioPharma, Inc. | 1.02 Million USD | 964.087% |
| Regen BioPharma, Inc. | 1.02 Million USD | 964.087% |
| NovAccess Global Inc. | -4.76 Million USD | -85.44% |
| Affymax, Inc. | -14.42 Million USD | 38.686% |
| Itoco Inc. | -1.86 Million USD | -373.195% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -99.076% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -429.898% |
| Mobile Lads Corp. | -2.26 Million USD | -290.758% |
| CytoDyn Inc. | -49.84 Million USD | 82.256% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -11090.262% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -3776.788% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -839.323% |
| SYBLEU INC | -180.3 Thousand USD | -4805.049% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -448.385% |
| International Stem Cell Corporation | -131 Thousand USD | -6651.145% |
| Bioxytran, Inc. | -4.28 Million USD | -106.635% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -16195.696% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -249.531% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 81.603% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -318.354% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1032.558% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -179.167% |
| Neutra Corp. | -233.46 Thousand USD | -3688.148% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 56.414% |
| PureTech Health plc | -65.69 Million USD | 86.538% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 58.414% |
| IXICO plc | -1.17 Million USD | -650.764% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 10.91% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 84.519% |
| CSL Limited | 2.64 Billion USD | 100.335% |
| Cellectis S.A. | -103.17 Million USD | 91.428% |